Access to the latest research — for scientists and people living with PD alike — in PDF's new scientific journal.
PDF Statement on Availability of Sinemet (R) in the US
- Jan 19 2011
In late December 2010, Merck & Co. Inc., informed the Parkinson’s community that in early 2011, there could be a temporary shortage of the brand name medications Sinemet® (carbidopa-levodopa) and Sinemet CR® (carbidopa-levodopa controlled release tablets) in the United States. The company has stated that any potential shortage is not related to product safety or quality issues, but is instead the result of a manufacturing supply source change, a process that requires regulatory approval.
Please click here to view the full letter from Merck on Sinemet.
If you experience difficulty in filling your prescription for Sinemet, please contact your doctor for information about potential short-term replacement options, including generic equivalents. The Food and Drug Administration (FDA) has shown generic Sinemet to be an effective Parkinson’s treatment. Please note that because of differences in manufacturing and formulation, dosing may need to be adjusted slightly.
If you have questions about the availability of Sinemet, please contact Merck's National Service Center at (800) NSC-MERCK or (800) 672-6372.
The PDF website will continue to keep readers up-to-date on this and all other important issues in Parkinson’s. If you have any questions, please contact our HelpLine at (800) 457-6676 or email email@example.com.
Source Date: Jan 19 2011